Redmile Group LLC Sells 126,818 Shares of Annexon, Inc. (NASDAQ:ANNX)

Redmile Group LLC reduced its stake in Annexon, Inc. (NASDAQ:ANNX) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,300,644 shares of the company’s stock after selling 126,818 shares during the period. Annexon accounts for 2.3% of Redmile Group LLC’s portfolio, making the stock its 16th largest position. Redmile Group LLC owned approximately 5.91% of Annexon worth $32,322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Point72 Asset Management L.P. raised its position in shares of Annexon by 5.6% in the 4th quarter. Point72 Asset Management L.P. now owns 5,626,796 shares of the company’s stock worth $28,865,000 after acquiring an additional 299,798 shares in the last quarter. Vanguard Group Inc. grew its stake in Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after purchasing an additional 576,625 shares during the period. Nuveen Asset Management LLC raised its holdings in Annexon by 6.5% in the fourth quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company’s stock worth $13,956,000 after purchasing an additional 164,915 shares in the last quarter. Candriam S.C.A. lifted its position in Annexon by 15.6% during the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock valued at $13,001,000 after buying an additional 341,431 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Annexon by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company’s stock valued at $11,142,000 after buying an additional 27,843 shares in the last quarter.

Annexon Trading Up 0.6%

Annexon stock opened at $1.76 on Thursday. Annexon, Inc. has a 12 month low of $1.29 and a 12 month high of $7.85. The company has a market capitalization of $193.10 million, a price-to-earnings ratio of -1.68 and a beta of 1.24. The business’s fifty day simple moving average is $1.94 and its two-hundred day simple moving average is $3.76.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, equities research analysts predict that Annexon, Inc. will post -0.96 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Needham & Company LLC decreased their price target on shares of Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. HC Wainwright decreased their target price on shares of Annexon from $20.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.